Juvaris BioTherapeutics Secures $25,000,000 Series B Funding

  • Feed Type
  • Date
    1/27/2010
  • Company Name
    Juvaris BioTherapeutics
  • Mailing Address
    866 Malcolm Road Burlingame, CA 94010
  • Company Description
    Juvaris BioTherapeutics is a new biotechnology company, started in February, 2003, that is developing potent active immunotherapeutic vaccines. Active immunotherapy involves the activation of the patient’s own immune system to combat disease as opposed to passive immunotherapy utilizing administration of preformed monoclonal antibodies.
  • Website
    http://www.juvaris.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will be used to advance Juvaris’ novel adjuvant platform of cationic-lipid DNA complexes, which are designed to significantly improve the quality and quantity of immune responses achievable with vaccines, along with the Company’s proprietary adjuvanted vaccine pipeline.
  • M&A Terms
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    Undisclosed

Trending on Xconomy